PCGF5 and CD4+/CD56+ hematodermic neoplasm: Moreover, ONECUT2-positive BPDCN patients expressed reduced levels of chromatin-repressor PCGF5, which reportedly competes with chromatin-activator AUTS2 (Figure 5C, Table S3) [35].